Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)

This lawsuit is for anyone who acquired securities in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) from March 17, 2022 through June 20, 2023.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by telling investors that the FDA was likely to accept the Company’s New Drug Application for the Company’s vitreoretinal lymphoma treatment, ADX-2191, when the Company knew that the tests the Company performed to prove the drug’s effectiveness were so poorly designed that, in fact, the FDA was unlikely to accept any test result.

On June 21, 2023, Aldeyra disclosed that it had received a Complete Response Letter from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s New Drug Application (“NDA”) for its vitreoretinal lymphoma treatment, ADX-2191. The Company revealed that “[a]lthough no safety or manufacturing issues with ADX-2191 were identified, the FDA stated that there was a ‘lack of substantial evidence of effectiveness’ due to ‘a lack of adequate and well-controlled investigations’ in the literature-based NDA submission.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) from March 17, 2022 through June 20, 2023 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.